Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia Authors: Farah Kalagi, Sulaiman Bah, Yasmin Algindan Published: 2026 ABSTRACT BackgroundReal-world evidence describing the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for adolescent obesity in Saudi Arabia remains limited. This study aimed to characterize current GLP-1 RA use, evaluate specialty-based variation in prescribing practices, and explore healthcare professionals’ perspectives on barriers to prescribing, training needs, and clinical guidance.MethodsThis was a national cross-sectional survey study conducted among physicians and clinical nutritionists practicing in Saudi Arabia between December 2024 and July 2025. The survey assessed prescribing practices, clinical perspectives, perceived barriers, and educational needs related to the use of GLP-1 receptor agonists for adolescent obesity. Comparisons across healthcare specialties were performed using chi-square and Fisher's exact tests, and reflexive thematic analysis was applied to responses to an optional open-ended question.ResultsA total of 140 healthcare professionals completed the survey, of whom 30% reported prescribing GLP-1 RAs for adolescent obesity. Pharmacological treatment was reported more frequently by endocrinologists and bariatric surgeons than by family medicine physicians, general pediatricians, and clinical nutritionists (p < 0.001). Among the 42 GLP-1 RA prescribers, reported treatment duration differed significantly across specialties (p = 0.017). Nausea was the most frequently reported adverse effect among prescribers (95%). Treatment cost, safety concerns, limited training, and the need for clearer national guidance were identified as major barriers. Qualitative findings reinforced the need for standardized prescribing criteria, monitoring recommendations, and multidisciplinary care.ConclusionsConsiderable specialty-based variation exists in GLP-1 RA prescribing practices for adolescent obesity in Saudi Arabia. These findings support the development of standardized national guidance, targeted professional education, and multidisciplinary care pathways to promote consistent, safe, and evidence-based prescribing. Introduction Adolescent obesity is a major global public health concern because of its increasing prevalence and association with adverse health outcomes. Similar concerns have been reported in Saudi Arabia, where the rising prevalence of obesity among young people has been associated with rapid social and lifestyle changes, urbanization, socioeconomic factors, and parental influences [[1], [2], [3]]. National estimates indicate that the prevalence of overweight and obesity among older children is 23% and 9.3%, respectively, highlighting the substantial burden of overweight and obesity in this population [4]. Adolescent obesity is associated with substantial physical and psychosocial consequences. Adolescents with obesity are at increased risk of type 2 diabetes, hypertension, dyslipidemia, sleep apnea, and other cardiometabolic complications [5]. Obesity may also adversely affect psychological well-being through low self-esteem, anxiety, depressive symptoms, weight-related stigma, bullying, and social isolation [[6], [7], [8]]. Lifestyle modification remains the cornerstone of adolescent obesity management; however, achieving and maintaining long-term BMI reduction is often challenging [9,10]. Although bariatric surgery may be considered for selected adolescents with severe obesity, its use is limited by concerns regarding long-term outcomes and the need for lifelong follow-up [[11], [12], [13]]. Consequently, pharmacological therapy has emerged as an important adjunct to lifestyle interventions. Among available anti-obesity medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained increasing attention. Current clinical practice guidelines recommend pharmacotherapy for eligible adolescents with obesity as an adjunct to health behavior and lifestyle treatment, rather than requiring failure of lifestyle interventions before treatment initiation [5]. Liraglutide was the first GLP-1 receptor agonist approved for chronic obesity management in adolescents aged 12 years and older [14]. Clinical trials and meta-analyses have demonstrated that GLP-1 RAs improve measures of adiposity and cardiometabolic outcomes, although gastrointestinal adverse effects remain the most commonly reported [[15], [16], [17]]. Despite these encouraging findings, several barriers continue to limit the implementation of GLP-1 receptor agonists in routine clinical practice. These include high treatment costs, limited insurance coverage, restricted access in certain healthcare settings, and ongoing concerns about long-term safety, particularly regarding potential effects on growth and pubertal development [18]. Although the efficacy and safety of GLP-1 receptor agonists have been demonstrated in clinical trials, real-world evidence describing specialty-specific prescribing practices remains limited, particularly in Saudi Arabia. Understanding these variations is essential for identifying gaps in clinical practice, informing national guidance, and promoting consistent, evidence-based obesity care for adolescents. Therefore, this study aimed to characterize current prescribing practices for GLP-1 receptor agonists for adolescent obesity in Saudi Arabia, evaluate variation across healthcare specialties, and explore healthcare professionals' perspectives on barriers to prescribing, training needs, and clinical guidance. Methods Study design This was a national cross-sectional survey study conducted between December 2024 and July 2025 among physicians and clinical nutritionists practicing in government and private healthcare settings in Saudi Arabia. The survey included one optional open-ended question, the responses to which were analyzed using reflexive thematic analysis. Study population Licensed physicians and clinical nutritionists practicing in Saudi Arabia were eligible regardless of prior GLP-1 RA prescribing experience. Questions related to prescribing practices were answered only by respondents who reported prescribing GLP-1 RA therapies (n = 42). Non-prescribers were included to capture broader perspectives from healthcare professionals on GLP-1 RA safety and effectiveness, barriers, training needs, and clinical guidance. Clinical nutritionists were included because of their role in multidisciplinary adolescent obesity care, particularly in providing nutritional assessment, dietary counseling, and ongoing nutritional support alongside pharmacological treatment. Independent pharmacological prescribing is not within their scope of practice in Saudi Arabia. The survey targeted healthcare professionals involved in managing obesity among adolescents aged 12–18 years. This age range was selected because it falls within the World Health Organization's definition of adolescence (10–19 years) and reflects the study's focus on GLP-1 RA therapies initiated at age 12 [19]. Data collection The questionnaire was designed to assess the views and attitudes of physicians and clinical nutritionists practicing in Saudi Arabia regarding the management of adolescent obesity. It was adapted, with permission from the authors, from a survey of healthcare professionals developed by Garvey et al. [20] Additional items were incorporated to address the objectives of the present study, resulting in a final questionnaire consisting of 30 items (Supplementary File 1). The questionnaire was self-administered online through Google Forms and was available in both Arabic and English. The survey was disseminated through multiple recruitment strategies to maximize participation among eligible healthcare professionals. These included snowball sampling through professional networks, open invitation via social media platforms (WhatsApp and LinkedIn), purposive recruitment through direct contact and hospital visits, and institution-assisted dissemination through the Saudi Commission for Health Specialties (SCFHS), which distributed the survey to physicians in the six targeted specialties. A non-probability sampling approach was used. Only participants who met the predefined inclusion criteria and belonged to one of the six targeted specialties were included in the final analysis. The SCFHS distributed the survey to 5001 physicians across the 6 targeted specialties, from whom 100 responses were received, corresponding to a response rate of 2.0% for this recruitment route. An additional 90 responses were obtained through direct and open recruitment. Because the number of healthcare professionals who viewed the open invitations was unknown, an overall response rate could not be calculated. Of the 190 responses received, 50 were excluded for failing to meet the predefined eligibility criteria, leaving 140 participants in the final analysis. The questionnaire was based on prior literature and a comprehensive review of studies on adolescent obesity. It contained 30 questions distributed into 5 sections:1.Demographic and professional characteristics2.Perceptions and attitudes toward adolescent obesity management3.Clinical experience with GLP-1 RA therapies4.Perceived safety, efficacy, and side effects of GLP-1 RA therapies5.Policy- and guideline-related barriers to GLP-1 RA prescribing. 1.Demographic and professional characteristics Demographic and professional characteristics 2.Perceptions and attitudes toward adolescent obesity management Perceptions and attitudes toward adolescent obesity management 3.Clinical experience with GLP-1 RA therapies Clinical experience with GLP-1 RA therapies 4.Perceived safety, efficacy, and side effects of GLP-1 RA therapies Perceived safety, efficacy, and side effects of GLP-1 RA therapies 5.Policy- and guideline-related barriers to GLP-1 RA prescribing. Policy- and guideline-related barriers to GLP-1 RA prescribing. Content validity was assessed by seven experts who reviewed the tool and suggested modifications. Face validity was evaluated with 20 physicians who shared characteristics with the target population and were excluded from the final sample. Participants were asked about clarity and ease of completion, and their feedback was used to refine the questionnaire. Confidentiality and anonymity were maintained by excluding personal identifiers, and all responses were securely stored and accessible only to the investigators. Cronbach's alpha was not computed because the questionnaire included multiple independent domains, rather than a single composite scale. Qualitative data were collected through written responses to a single open-ended question embedded in the survey: “What should policies or guidelines regarding using GLP-1 in adolescents include?” This approach enabled participants to share their views and experiences on the use of GLP-1 RAs in the management of adolescent obesity. Incomplete responses were excluded from the final analysis. Sample size and sampling procedure The required sample size was calculated using OpenEpi (Version 3.01) with the following parameters: a population size of approximately 100,000 physicians and an anticipated prevalence of 20%. This estimate was used because of the lack of prior local data on GLP-1 RA prescribing for adolescent obesity. A 95% confidence level and 7% precision were applied. The estimated minimum sample size was 126. To account for potential non-response, additional questionnaires were distributed. The final analysis included 140 complete and eligible responses. Participants were classified into six professional groups for descriptive analyses: general pediatrics, adult endocrinology, pediatric endocrinology, bariatric surgery, family medicine, and clinical nutrition. For specialty-based comparative analyses, adult and pediatric endocrinologists were grouped with bariatric surgeons, family medicine physicians were grouped with general pediatricians, and clinical nutritionists were analyzed separately. The qualitative data were derived from the same participants who completed the cross-sectional survey. Of 140 respondents, 62 answered the open-ended question, forming the qualitative dataset. Respondents included physicians from various specialties, including general pediatrics, adult and pediatric endocrinology, family medicine, and bariatric surgery, as well as CNs. Since this qualitative component was embedded within the survey, no separate qualitative sampling strategy or assessment of data saturation was employed. Eligibility criteria Eligible participants were licensed physicians practicing in general pediatrics, adult endocrinology, pediatric endocrinology, bariatric surgery, or family medicine, as well as licensed clinical nutritionists working in government or private healthcare settings in Saudi Arabia. Prior GLP-1 RA prescribing experience was not required for participation. Healthcare professionals practicing outside Saudi Arabia or belonging to professional groups other than the six predefined groups were excluded. These included nurses, pharmacists, and other allied healthcare professionals, excluding clinical nutritionists. Statistical methods Quantitative data were analyzed using IBM SPSS Statistics, version 24.0 (IBM Corp., Armonk, NY, USA). Categorical variables were summarized as frequencies and percentages. Associations between categorical variables were examined using the chi-square test or Fisher's exact test, as appropriate. All statistical tests were two-sided, and statistical significance was set at p < 0.05. All closed-ended survey items were mandatory; therefore, there were no missing quantitative data among the 140 included responses. The open-ended question was optional, and the qualitative analysis included responses from the 62 participants who provided one. Written responses to the optional open-ended question regarding recommended policies or guidelines for GLP-1 RA use in adolescents were analyzed using reflexive thematic analysis, guided by Braun and Clarke's six-phase framework [21]. One researcher conducted the coding and theme development using NVivo 15, and the resulting themes and interpretations were discussed with the other authors. Patient and public involvement Patients and members of the public were not involved in the design, conduct, reporting, or dissemination plans of this research. Ethics approval and informed consent This study was approved by the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB-PGS-2024-03-742). Participation was voluntary and anonymous. Before beginning the survey, participants were informed about the purpose of the study and the voluntary nature of participation. Completion and submission of the questionnaire constituted implied informed consent. No personal identifiers were collected, and all responses were handled confidentially. The study was conducted in accordance with the Declaration of Helsinki [22]. Results Participant characteristics A total of 140 healthcare professionals completed the survey. General pediatricians represented the largest specialty group (35%), followed by family medicine physicians (24%), clinical nutritionists (15%), adult endocrinologists (13%), pediatric endocrinologists (11%), and bariatric surgeons (2%). Most respondents were female (61%), Saudi nationals (59%), worked in government healthcare settings (59%), and had at least 10 years of professional experience (58%). Participants were recruited from all regions of Saudi Arabia, with most practicing in the Central (51%) and Eastern (27%) regions (Table 1).Table 1Demographic characteristics of the respondents (N = 140).Table 1(N = 140)n%GenderMale5439%Female8661%NationalitySaudi8359%Non-Saudi5741%Highest Education LevelMD/Academic8158%Specialist/Fellow1410%Resident Physician2417%Nutritionist2115%Medical SpecialtyGeneral Pediatrician4935%Adult Endocrinologist1813%Pediatric Endocrinologist1611%Bariatric Surgeon32%Family Medicine3324%Nutritionist2115%Region of Saudi ArabiaCentral7251%Eastern3827%Northern86%Southern86%Western1410%Government or the Private healthcare sectorGovernment Hospital (General or Specialist)8359%Primary Health Center1611%Private Hospital2921%Private Clinic129%Years of Experience<5 years2719%5–9 years3122%10–14 years3827%15+ years4431%Abbreviation: MD, Doctor of Medicine. Table 1Demographic characteristics of the respondents (N = 140).Table 1(N = 140)n%GenderMale5439%Female8661%NationalitySaudi8359%Non-Saudi5741%Highest Education LevelMD/Academic8158%Specialist/Fellow1410%Resident Physician2417%Nutritionist2115%Medical SpecialtyGeneral Pediatrician4935%Adult Endocrinologist1813%Pediatric Endocrinologist1611%Bariatric Surgeon32%Family Medicine3324%Nutritionist2115%Region of Saudi ArabiaCentral7251%Eastern3827%Northern86%Southern86%Western1410%Government or the Private healthcare sectorGovernment Hospital (General or Specialist)8359%Primary Health Center1611%Private Hospital2921%Private Clinic129%Years of Experience<5 years2719%5–9 years3122%10–14 years3827%15+ years4431%Abbreviation: MD, Doctor of Medicine. Demographic characteristics of the respondents (N = 140). Abbreviation: MD, Doctor of Medicine. Knowledge, management strategies, and challenges Most respondents rated their knowledge of adolescent obesity as good or excellent. Overall, 70% of respondents rated their familiarity with the Saudi guidelines for preventing and managing overweight and obesity in children and adolescents as good or excellent. Lifestyle modification, including dietary intervention and physical activity, was the most commonly reported management approach, whereas pharmacological treatment and bariatric surgery were reported less frequently. Limited parental awareness and poor adherence to treatment recommendations were identified as the most common challenges in the management of adolescent obesity. GLP-1 RA prescribing patterns and safety Overall, 30% of respondents reported prescribing GLP-1 RAs for adolescent obesity. Among prescribers, treatment was most commonly initiated for adolescents aged 12–14 years with a BMI at or above the 95th percentile, particularly when obesity was accompanied by at least 1 obesity-related comorbidity. The most frequently reported comorbidities were prediabetes, sleep apnea, type 2 diabetes, and Metabolic dysfunction-associated steatotic liver disease (MASLD). Liraglutide was the most frequently prescribed GLP-1 RA (76%), followed by semaglutide in its type 2 diabetes-indicated formulation (43%) and obesity-indicated formulation (14%). More than half of prescribers (55%) continued treatment until the target weight was achieved, whereas 26% continued treatment as long as it was tolerated. The lowest recommended adult dose was the most frequently used dosing strategy (52%). No respondent reported discontinuing treatment because of medical complications, and lifelong therapy was rarely prescribed (2%) (Table 2).Table 2GLP-1 RA formulations, treatment duration, and dosing strategies reported by prescribers (n = 42).Table 2n%What is the scientific name of the GLP-1 RAa formulation you use to treat obesity in adolescents?bLiraglutide3276%Semaglutide (type 2 diabetes-indicated formulation)1843%Semaglutide (obesity-indicated formulation)614%Other25%What is the length of the GLP-1 RAa course you prescribe?0–6 months, regardless of whether the patient reaches the target weight717%Until reaching the target weight2355%As long as the patient tolerates1126%For life12%Stopped owing to medical complications00%What doses of GLP-1 RAa do you use for children or adolescents?The lowest recommended dose for adults2252%The same dose is used in adult obesity treatment1843%Other25%Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.aGLP-1: Glucagon-like peptide-1.bMore than one option could be selected. Table 2GLP-1 RA formulations, treatment duration, and dosing strategies reported by prescribers (n = 42).Table 2n%What is the scientific name of the GLP-1 RAa formulation you use to treat obesity in adolescents?bLiraglutide3276%Semaglutide (type 2 diabetes-indicated formulation)1843%Semaglutide (obesity-indicated formulation)614%Other25%What is the length of the GLP-1 RAa course you prescribe?0–6 months, regardless of whether the patient reaches the target weight717%Until reaching the target weight2355%As long as the patient tolerates1126%For life12%Stopped owing to medical complications00%What doses of GLP-1 RAa do you use for children or adolescents?The lowest recommended dose for adults2252%The same dose is used in adult obesity treatment1843%Other25%Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.aGLP-1: Glucagon-like peptide-1.bMore than one option could be selected. GLP-1 RA formulations, treatment duration, and dosing strategies reported by prescribers (n = 42). Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist. GLP-1: Glucagon-like peptide-1. More than one option could be selected. Among prescribers, the most frequently reported parental concerns were treatment safety and potential adverse effects (76%) and treatment cost (38%), whereas 33% reported that parents had expressed no concerns. Nausea was the most frequently reported adverse effect (95%), followed by diarrhea (38%) and headache (36%). Attitudes toward GLP-1 RA use, training, and policy Overall, 46% of respondents agreed or strongly agreed that GLP-1 RAs are safe and effective for treating adolescent obesity, whereas 44% reported a neutral response (Fig. 1). Most respondents supported insurance coverage for GLP-1 RAs (74%) and emphasized the need for updated national policies or clinical guidelines governing their use in adolescents (86%). However, only 22% believed that sufficient training and educational resources were available for healthcare professionals. Opinions regarding dispensing GLP-1 RAs without a prescription were mixed.Fig. 1Respondents' perceptions of the safety and effectiveness of GLP-1 RAs for adolescent obesity. Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist. Respondents' perceptions of the safety and effectiveness of GLP-1 RAs for adolescent obesity. Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist. Associations by specialty and healthcare sector Significant variation in adolescent obesity management was observed across healthcare specialties. Pharmacological treatment was reported more frequently by endocrinologists and bariatric surgeons (89%) than by family medicine physicians and general pediatricians (17%) or clinical nutritionists (5%) (p < 0.001). Similarly, surgical intervention was reported more frequently by endocrinologists and bariatric surgeons (27%) than by family medicine physicians and general pediatricians (9%), whereas no clinical nutritionists reported recommending surgery (p = 0.004). In contrast, the use of lifestyle interventions, including dietary modification and physical activity, did not differ significantly across specialties (Table 3).Table 3Comparison of adolescent obesity management strategies by professional group.Table 3Professional groupp-valueAdult/Pediatric Endocrinologist + Bariatric Surgeon (n = 37)Family Medicine/General Pediatrician (n = 82)Nutritionist (n = 21)n%n%n%Diet modificationYes3389%8098%2095%0.14bNo411%22%15%Physical activityYes3286%7693%2095%0.48bNo514%67%15%MedicationsYes3389%1417%15%<0.001aNo411%6883%2095%Behavioral therapyYes1849%5770%1571%0.07aNo1951%2530%629%Surgical interventionYes1027%79%00%0.004bNo2773%7591%21100%aChi-Square test.bFisher's Exact test. Table 3Comparison of adolescent obesity management strategies by professional group.Table 3Professional groupp-valueAdult/Pediatric Endocrinologist + Bariatric Surgeon (n = 37)Family Medicine/General Pediatrician (n = 82)Nutritionist (n = 21)n%n%n%Diet modificationYes3389%8098%2095%0.14bNo411%22%15%Physical activityYes3286%7693%2095%0.48bNo514%67%15%MedicationsYes3389%1417%15%<0.001aNo411%6883%2095%Behavioral therapyYes1849%5770%1571%0.07aNo1951%2530%629%Surgical interventionYes1027%79%00%0.004bNo2773%7591%21100%aChi-Square test.bFisher's Exact test. Comparison of adolescent obesity management strategies by professional group. Chi-Square test. Fisher's Exact test. Perceptions of GLP-1 RAs varied significantly across specialties. Endocrinologists and bariatric surgeons were more likely to agree that GLP-1 RAs are safe and effective for adolescent obesity than family medicine physicians, general pediatricians, and clinical nutritionists (p < 0.001) (Table 4). Familiarity with the Saudi obesity management guidelines also differed significantly across specialties (p = 0.01), with greater familiarity reported by endocrinologists, bariatric surgeons, and clinical nutritionists.Table 4Comparison of perceived GLP-1 RA safety and effectiveness by professional group and healthcare sector.Table 4To what extent do you agree that GLP-1 is safe and effective for treating obesity in children and adolescentsp-valueAgree/Strongly AgreeNeutralDisagree/Strongly DisagreeMedical SpecialtyAdult/Pediatric Endocrinologist + Bariatric Surgeon3232<0.001b86%8%5%Family Medicine/General Pediatrician2746933%56%11%Nutritionist512424%57%19%Government or Private healthcare sectorGovernment Hospital/Primary Health Center4443120.69a44%43%12%Private Hospital/Private Clinic/Other2018349%44%7%Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.aChi-square.bFisher Exact test. Table 4Comparison of perceived GLP-1 RA safety and effectiveness by professional group and healthcare sector.Table 4To what extent do you agree that GLP-1 is safe and effective for treating obesity in children and adolescentsp-valueAgree/Strongly AgreeNeutralDisagree/Strongly DisagreeMedical SpecialtyAdult/Pediatric Endocrinologist + Bariatric Surgeon3232<0.001b86%8%5%Family Medicine/General Pediatrician2746933%56%11%Nutritionist512424%57%19%Government or Private healthcare sectorGovernment Hospital/Primary Health Center4443120.69a44%43%12%Private Hospital/Private Clinic/Other2018349%44%7%Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist.aChi-square.bFisher Exact test. Comparison of perceived GLP-1 RA safety and effectiveness by professional group and healthcare sector. Abbreviation: GLP-1 RA, glucagon-like peptide-1 receptor agonist. Chi-square. Fisher Exact test. Among the 42 GLP-1 RA prescribers, reported treatment duration differed significantly across specialties (p = 0.017). Family medicine physicians/general pediatricians were more likely to report treatment for 0–6 months than endocrinologists (50% vs. 7%), whereas endocrinologists more frequently reported treatment until the target weight was achieved (60% vs. 40%) or for as long as treatment was tolerated (30% vs. 10%). However, no significant specialty-based differences were observed in the reported age at treatment initiation, BMI thresholds for prescribing, dosing strategies, or GLP-1 RA formulation used. Comparisons by healthcare sector showed no significant differences in reported GLP-1 RA prescribing, perceptions of treatment safety and effectiveness, or adolescent obesity management strategies. Among prescribers, the GLP-1 RA formulation used differed significantly across healthcare sectors (p = 0.008), with liraglutide reported more frequently in government settings and semaglutide more frequently in private settings. Qualitative findings Of the 140 survey respondents, 62 provided written responses to the optional open-ended question regarding recommended policies or clinical guidelines for GLP-1 RA use in adolescents. Reflexive thematic analysis identified 6 themes: clinical practice and prescribing considerations, instructions for use, education and awareness, scientific evidence and research, usage policies, and safety and effectiveness (Table 5).Table 5Overview of themes identified through reflexive thematic analysis of the open-ended responses.Table 5ThemeSummary of findingsIllustrative quotationClinical practice and prescribing considerationsParticipants emphasized the need for standardized prescribing criteria, including patient selection, BMI thresholds, treatment initiation and discontinuation, baseline assessment, and integration of lifestyle interventions with GLP-1 RA therapy.“Clear guidance about when to start and when to stop based on BMI & target weight range.”Instructions for useRespondents requested practical guidance regarding treatment duration, dose adjustment, and recommendations for treatment discontinuation and reinitiation.“Certain time limits for using injections.”Education and awarenessParticipants highlighted the importance of educating adolescents, parents, and healthcare professionals regarding obesity management, medication use, and lifestyle modification.“Important to educate the child and their family on how to use the medication correctly.”Scientific evidence and researchRespondents emphasized the need for additional long-term research to support evidence-based prescribing in adolescents.“Science-based recommendation rather than biased personal opinions.”Usage policiesParticipants recommended clear national guidelines, standardized treatment protocols, pharmacy dispensing regulations, and parental consent requirements.“Establishing clear policies for dispensing the treatment from pharmacies.”Safety and effectivenessParticipants emphasized monitoring treatment response, adverse effects, and long-term safety throughout therapy.“Continuous monitoring of blood sugar levels and any side effects.”Abbreviations: BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist. Table 5Overview of themes identified through reflexive thematic analysis of the open-ended responses.Table 5ThemeSummary of findingsIllustrative quotationClinical practice and prescribing considerationsParticipants emphasized the need for standardized prescribing criteria, including patient selection, BMI thresholds, treatment initiation and discontinuation, baseline assessment, and integration of lifestyle interventions with GLP-1 RA therapy.“Clear guidance about when to start and when to stop based on BMI & target weight range.”Instructions for useRespondents requested practical guidance regarding treatment duration, dose adjustment, and recommendations for treatment discontinuation and reinitiation.“Certain time limits for using injections.”Education and awarenessParticipants highlighted the importance of educating adolescents, parents, and healthcare professionals regarding obesity management, medication use, and lifestyle modification.“Important to educate the child and their family on how to use the medication correctly.”Scientific evidence and researchRespondents emphasized the need for additional long-term research to support evidence-based prescribing in adolescents.“Science-based recommendation rather than biased personal opinions.”Usage policiesParticipants recommended clear national guidelines, standardized treatment protocols, pharmacy dispensing regulations, and parental consent requirements.“Establishing clear policies for dispensing the treatment from pharmacies.”Safety and effectivenessParticipants emphasized monitoring treatment response, adverse effects, and long-term safety throughout therapy.“Continuous monitoring of blood sugar levels and any side effects.”Abbreviations: BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist. Overview of themes identified through reflexive thematic analysis of the open-ended responses. Abbreviations: BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist. Clinical practice and prescribing considerations This was the most frequently identified theme. Participants emphasized the need for standardized prescribing criteria, including clear recommendations for patient selection, BMI thresholds, treatment initiation and discontinuation, baseline assessment, and treatment goals. Several respondents stressed that GLP-1 RA therapy should be integrated with lifestyle modification, behavioral support, and nutritional follow-up rather than used as a stand-alone intervention. Others highlighted the importance of defining treatment indications, considering patient age, and ensuring appropriate medical supervision. Instructions for use Participants requested practical recommendations regarding treatment duration, dose adjustment, and criteria for treatment discontinuation or reinitiation. Many expressed uncertainty about the optimal duration of therapy and emphasized that dosing should be individualized according to patient characteristics. Education and awareness Participants highlighted the importance of educating adolescents, parents, and healthcare professionals about adolescent obesity management, appropriate GLP-1 RA use, and lifestyle modification. Many also emphasized the need for additional professional training and greater public awareness. Scientific evidence and research Participants emphasized the need for additional long-term studies evaluating the safety and effectiveness of GLP-1 RAs in adolescents. They also stressed that future clinical recommendations should be based on robust scientific evidence rather than expert opinion alone. Usage policies Participants called for clear national policies and standardized clinical guidelines governing the use of GLP-1 RAs in adolescents. Suggested components included prescribing criteria, standardized treatment protocols, pharmacy dispensing regulations, and parental consent requirements. Safety and effectiveness Participants emphasized the importance of monitoring treatment response, adverse effects, and long-term safety throughout GLP-1 RA therapy. Regular follow-up and adherence to evidence-based safety recommendations were viewed as essential components of clinical practice. Discussion This study identified specialty-based variation in the pharmacological management of adolescent obesity and in healthcare professionals’ perceptions and practices related to GLP-1 RAs in Saudi Arabia. Overall, 30% of respondents reported prescribing GLP-1 RAs. Endocrinologists and bariatric surgeons reported substantially greater use of pharmacological treatment (89%) than family medicine physicians and general pediatricians (17%), highlighting a marked specialty-based difference and reinforcing the need for targeted professional education to support evidence-based obesity pharmacotherapy across specialties. Although nearly half of respondents considered GLP-1 RAs safe and effective, a similarly large proportion reported neutrality, indicating ongoing uncertainty about their routine use in adolescent obesity management. This uncertainty may reflect differences in clinical exposure, experience, and familiarity with obesity pharmacotherapy, as well as limited long-term safety data. The qualitative findings complemented the quantitative results, with participants consistently requesting clearer prescribing criteria, standardized treatment pathways, and specific recommendations for treatment initiation, monitoring, and discontinuation. This uncertainty about treatment duration was also reflected in the quantitative findings, with only 2% of prescribers reporting lifelong GLP-1 RA therapy. The emphasis on discontinuation guidance is clinically relevant given evidence of weight regain after GLP-1 RA withdrawal [23]. Together, these findings highlight the need for structured national guidance to support more consistent clinical practice. Concerns regarding safety and tolerability appeared to influence reported prescribing decisions. Nausea was the most frequently reported adverse effect among prescribers, while treatment safety and potential adverse effects were the most commonly reported parental concerns. Participants emphasized the importance of appropriate patient selection, gradual dose escalation, and regular monitoring. These findings are consistent with pediatric studies reporting gastrointestinal adverse events as the most common treatment-related effects, while uncertainty remains regarding potential long-term effects on growth and pubertal development [15,17]. The qualitative responses similarly emphasized continuous monitoring, long-term safety evaluation, and regular assessment of treatment effectiveness. Collectively, these findings support the need for structured monitoring and evidence-based safety recommendations when prescribing GLP-1 RAs to adolescents. Among GLP-1 RA prescribers, treatment was generally initiated during early adolescence, primarily among patients with obesity who met the ≥95th-percentile BMI threshold. While prescribing criteria appeared relatively consistent, treatment duration differed across specialties. Endocrinologists were more likely to report continuing therapy until the target weight was achieved. In adolescents, treatment goals should be considered in the context of BMI-for-age trajectories and ongoing growth rather than focusing solely on a fixed body weight. Variability in pediatric obesity pharmacotherapy has also been reported internationally, including across pediatric weight-management programs, with differences in the timing and patterns of medication use [24,25]. Notably, 52% of prescribers selected “the lowest recommended dose for adults” when reporting their dosing practice. This survey item assessed general dosing practice rather than specific starting doses or subsequent dose escalation. Current Saudi guidance supports structured dose escalation for liraglutide in adolescents [26]. Several barriers to implementing GLP-1 RA therapies were identified at both the family and healthcare system levels. Participants reported challenges related to treatment cost, limited parental awareness, adherence difficulties, and restricted access to multidisciplinary obesity services. Inconsistent familiarity with clinical guidelines and limited educational resources may have further contributed to variations in prescribing practices across specialties. Together, these findings suggest that improving access to multidisciplinary obesity services, expanding professional education, and developing clearer national guidance may help reduce variation in prescribing practices across specialties [5,20,26]. These findings were reinforced by the qualitative responses, in which participants emphasized the importance of parental education, standardized national policies, and the integration of GLP-1 RA therapy with lifestyle modification, rather than using pharmacological treatment in isolation. In addition, strong support for insurance coverage and concerns about dispensing practices underscore the importance of addressing system-level factors that influence equitable access to, and appropriate regulation of, GLP-1 RA therapies. Current Saudi national guidelines include pharmacotherapy as part of comprehensive obesity management and provide recommendations regarding anti-obesity medications [26]. In comparison, the 2023 AAP guideline specifically recommends offering pharmacotherapy to adolescents aged 12 years and older with obesity, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment [5]. The present findings nevertheless indicate a need for clearer, more standardized national guidance on GLP-1 RA prescribing, treatment duration, monitoring, and discontinuation in adolescents. The qualitative findings further reinforced this need, with respondents repeatedly calling for standardized national guidance on prescribing criteria, treatment protocols, monitoring requirements, and pharmacy dispensing regulations. Strengths and limitations A major strength of this study is that it is among the first national studies in Saudi Arabia to examine specialty-based variation in GLP-1 RA prescribing practices for adolescent obesity and to integrate quantitative and qualitative findings. Furthermore, the inclusion of an open-ended question offered valuable insights into participants’ perspectives and experiences regarding GLP-1 RA use in adolescents. The mixed-methods approach complemented the quantitative findings with qualitative insights, providing a more comprehensive understanding of current prescribing practices and perceived barriers. Limitations should be acknowledged. The cross-sectional design of the study does not allow causal inferences, and the use of self-reported responses may introduce reporting bias. The non-probability sampling strategy and modest sample size may limit the representativeness of the findings. Furthermore, the qualitative findings were derived from brief written responses rather than in-depth interviews. Therefore, the findings should be interpreted in the context of the Saudi healthcare system and may not generalize to other healthcare settings. Conclusion GLP-1 RAs are used to manage adolescent obesity in Saudi Arabia; however, considerable variation persists in prescribing practices, clinical perceptions, and treatment duration across healthcare specialties. The integration of quantitative and qualitative findings supports the following clinical takeaways:•Standardized national guidance is needed to support consistent patient selection, treatment initiation, monitoring, and discontinuation.•Targeted professional education may improve confidence and reduce specialty-based variation in evidence-based prescribing.•GLP-1 RA therapy should be integrated with lifestyle modification, nutritional support, and multidisciplinary follow-up rather than used as a stand-alone intervention. •Standardized national guidance is needed to support consistent patient selection, treatment initiation, monitoring, and discontinuation. Standardized national guidance is needed to support consistent patient selection, treatment initiation, monitoring, and discontinuation. •Targeted professional education may improve confidence and reduce specialty-based variation in evidence-based prescribing. Targeted professional education may improve confidence and reduce specialty-based variation in evidence-based prescribing. •GLP-1 RA therapy should be integrated with lifestyle modification, nutritional support, and multidisciplinary follow-up rather than used as a stand-alone intervention. GLP-1 RA therapy should be integrated with lifestyle modification, nutritional support, and multidisciplinary follow-up rather than used as a stand-alone intervention. CRediT authorship contribution statement Farah R. Kalagi: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Writing – original draft. Yasmin Y. Algindan: Conceptualization, Methodology, Supervision, Writing – review and editing. Sulaiman Bah: Supervision, Writing – review and editing. All authors reviewed, approved the final manuscript, and agreed to be accountable for all aspects of the work. Authorship statement All authors meet the journal's authorship criteria, have made substantial contributions to the study, and take responsibility for the integrity of the work. Ethical adherence and ethical review This was a cross-sectional survey study and not a prospective clinical trial involving assignment to an intervention. The study was approved by the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB-PGS-2024-03-742) and conducted in accordance with the Declaration of Helsinki. Participation was voluntary and anonymous, and completion and submission of the questionnaire constituted implied informed consent. Data sharing statement The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. Reporting guidelines This study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [27]. Declaration of generative AI and AI-assisted technologies in the writing process AI tools were used only for limited language assistance during manuscript preparation. No AI tools were used for study design, data collection, data analysis, interpretation of results, or scientific decision-making. The final manuscript was reviewed and approved by all authors. Source of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.